PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ATOM vs. PFE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ATOM and PFE is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

ATOM vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atomera Incorporated (ATOM) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

0.00%100.00%200.00%300.00%400.00%500.00%SeptemberOctoberNovemberDecember2025February
114.95%
-7.94%
ATOM
PFE

Key characteristics

Sharpe Ratio

ATOM:

-0.09

PFE:

0.00

Sortino Ratio

ATOM:

0.72

PFE:

0.17

Omega Ratio

ATOM:

1.10

PFE:

1.02

Calmar Ratio

ATOM:

-0.11

PFE:

0.00

Martin Ratio

ATOM:

-0.26

PFE:

0.00

Ulcer Index

ATOM:

41.31%

PFE:

9.59%

Daily Std Dev

ATOM:

114.91%

PFE:

23.17%

Max Drawdown

ATOM:

-94.73%

PFE:

-54.82%

Current Drawdown

ATOM:

-86.39%

PFE:

-50.79%

Fundamentals

Market Cap

ATOM:

$193.01M

PFE:

$146.72B

EPS

ATOM:

-$0.68

PFE:

$1.41

PEG Ratio

ATOM:

0.00

PFE:

0.18

Total Revenue (TTM)

ATOM:

$112.00K

PFE:

$63.63B

Gross Profit (TTM)

ATOM:

-$425.00K

PFE:

$41.72B

EBITDA (TTM)

ATOM:

-$13.18M

PFE:

$16.34B

Returns By Period

In the year-to-date period, ATOM achieves a -45.52% return, which is significantly lower than PFE's -0.80% return.


ATOM

YTD

-45.52%

1M

-26.85%

6M

114.97%

1Y

-5.46%

5Y*

5.11%

10Y*

N/A

PFE

YTD

-0.80%

1M

0.07%

6M

-7.93%

1Y

-0.28%

5Y*

-0.95%

10Y*

1.69%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ATOM vs. PFE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATOM
The Risk-Adjusted Performance Rank of ATOM is 4444
Overall Rank
The Sharpe Ratio Rank of ATOM is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of ATOM is 5151
Sortino Ratio Rank
The Omega Ratio Rank of ATOM is 5050
Omega Ratio Rank
The Calmar Ratio Rank of ATOM is 3838
Calmar Ratio Rank
The Martin Ratio Rank of ATOM is 4040
Martin Ratio Rank

PFE
The Risk-Adjusted Performance Rank of PFE is 4242
Overall Rank
The Sharpe Ratio Rank of PFE is 4545
Sharpe Ratio Rank
The Sortino Ratio Rank of PFE is 3737
Sortino Ratio Rank
The Omega Ratio Rank of PFE is 3636
Omega Ratio Rank
The Calmar Ratio Rank of PFE is 4545
Calmar Ratio Rank
The Martin Ratio Rank of PFE is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ATOM vs. PFE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Atomera Incorporated (ATOM) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ATOM, currently valued at -0.09, compared to the broader market-2.000.002.00-0.090.00
The chart of Sortino ratio for ATOM, currently valued at 0.72, compared to the broader market-4.00-2.000.002.004.006.000.720.17
The chart of Omega ratio for ATOM, currently valued at 1.10, compared to the broader market0.501.001.502.001.101.02
The chart of Calmar ratio for ATOM, currently valued at -0.11, compared to the broader market0.002.004.006.00-0.110.00
The chart of Martin ratio for ATOM, currently valued at -0.26, compared to the broader market0.0010.0020.0030.00-0.260.00
ATOM
PFE

The current ATOM Sharpe Ratio is -0.09, which is lower than the PFE Sharpe Ratio of 0.00. The chart below compares the historical Sharpe Ratios of ATOM and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00SeptemberOctoberNovemberDecember2025February
-0.09
0.00
ATOM
PFE

Dividends

ATOM vs. PFE - Dividend Comparison

ATOM has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.53%.


TTM20242023202220212020201920182017201620152014
ATOM
Atomera Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
6.53%6.33%5.70%3.12%2.64%3.91%3.68%3.12%3.53%3.69%3.47%3.34%

Drawdowns

ATOM vs. PFE - Drawdown Comparison

The maximum ATOM drawdown since its inception was -94.73%, which is greater than PFE's maximum drawdown of -54.82%. Use the drawdown chart below to compare losses from any high point for ATOM and PFE. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%SeptemberOctoberNovemberDecember2025February
-86.39%
-50.79%
ATOM
PFE

Volatility

ATOM vs. PFE - Volatility Comparison

Atomera Incorporated (ATOM) has a higher volatility of 65.49% compared to Pfizer Inc. (PFE) at 6.49%. This indicates that ATOM's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
65.49%
6.49%
ATOM
PFE

Financials

ATOM vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between Atomera Incorporated and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab